Cervical carcinoma (squamous predominant + adeno) · line 1 · Cisplatin radiosensitization (concurrent with EBRT + brachytherapy)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-CISPLATIN-RADIOSENS`

ID	`IND-CERVICAL-LOCALLY-ADVANCED-CRT`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-CERVICAL`
Sources	`SRC-ESMO-CERVICAL-2024` `SRC-NCCN-CERVICAL-2025`

Notes

PARTIAL — brachytherapy + EBRT modality not modellable per PROPOSAL §17. This Indication captures cisplatin chemo backbone + free-text RT description.

Used By

Algorithms

ALGO-CERVICAL-LOCALLY-ADVANCED-1L - ALGO-CERVICAL-LOCALLY-ADVANCED-1L

Indication

IND-CERVICAL-METASTATIC-1L-PEMBRO-CHEMO-BEV - IND-CERVICAL-METASTATIC-1L-PEMBRO-CHEMO-BEV
IND-VULVAR-VAGINAL-SCC-LA-1L-CISPLATIN-RT - IND-VULVAR-VAGINAL-SCC-LA-1L-CISPLATIN-RT